Bank of New York Mellon’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-124,164
| Closed | -$1.63M | – | 4201 |
|
|
2025
Q4 | $1.63M | Buy |
124,164
+9,866
| +9% | +$118K | ﹤0.01% | 2964 |
|
|
2025
Q3 | $832K | Sell |
114,298
-11,418
| -9% | -$77.3K | ﹤0.01% | 3317 |
|
|
2025
Q2 | $674K | Buy |
125,716
+6,696
| +6% | +$32.5K | ﹤0.01% | 3344 |
|
|
2025
Q1 | $636K | Buy |
119,020
+193
| +0.2% | +$1.35K | ﹤0.01% | 3331 |
|
|
2024
Q4 | $1.06M | Buy |
118,827
+892
| +0.8% | +$9.47K | ﹤0.01% | 3125 |
|
|
2024
Q3 | $1.3M | Sell |
117,935
-21,136
| -15% | -$235K | ﹤0.01% | 2992 |
|
|
2024
Q2 | $1.27M | Buy |
139,071
+8,965
| +7% | +$87.5K | ﹤0.01% | 3060 |
|
|
2024
Q1 | $1.83M | Buy |
130,106
+37,853
| +41% | +$471K | ﹤0.01% | 2808 |
|
|
2023
Q4 | $709K | Buy |
92,253
+22,500
| +32% | +$124K | ﹤0.01% | 3365 |
|
|
2023
Q3 | $520K | Buy |
69,753
+330
| +0.5% | +$2.81K | ﹤0.01% | 3524 |
|
|
2023
Q2 | $578K | Buy |
+69,423
| New | +$801K | ﹤0.01% | 3510 |
|
|
2021
Q3 | – | Sell |
-2,549
| Closed | -$32K | – | 4521 |
|
|
2021
Q2 | $32K | Sell |
2,549
-7,972
| -76% | -$104K | ﹤0.01% | 4367 |
|
|
2021
Q1 | $183K | Buy |
10,521
+1,749
| +20% | +$31.6K | ﹤0.01% | 4078 |
|
|
2020
Q4 | $113K | Sell |
8,772
-362
| -4% | -$6.45K | ﹤0.01% | 4060 |
|
|
2020
Q3 | $339K | Buy |
9,134
+1,954
| +27% | +$77.4K | ﹤0.01% | 3669 |
|
|
2020
Q2 | $276K | Buy |
+7,180
| New | +$256K | ﹤0.01% | 3711 |
|
|
2018
Q2 | – | Sell |
-234
| Closed | -$25K | – | 4211 |
|
|
2018
Q1 | $25K | Buy |
+234
| New | +$23.4K | ﹤0.01% | 4255 |
|
|
2016
Q2 | – | Sell |
-206
| Closed | -$63K | – | 4321 |
|
|
2016
Q1 | $63K | Buy |
206
+10
| +5% | +$3.45K | ﹤0.01% | 4048 |
|
|
2015
Q4 | $93K | Buy |
196
+12
| +7% | +$5.76K | ﹤0.01% | 4080 |
|
|
2015
Q3 | $89K | Buy |
+184
| New | +$131K | ﹤0.01% | 4136 |
|
Bank of New York Mellon's ATXS Position: Q1 2026 in Review
Bank of New York Mellon sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 124,164 shares — an estimated $1.63M sold.
Bank of New York Mellon first reported a position in ATXS in Q3 2015 and held it in 20 quarters. The position peaked at $1.83M in Q1 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Bank of New York Mellon reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Bank of New York Mellon sold 124,164 Astria Therapeutics shares in Q1 2026, an estimated $1.63M.
- Bank of New York Mellon first reported a position in Astria Therapeutics in Q3 2015 and held it in 20 quarters.
- Bank of New York Mellon's Astria Therapeutics position peaked at $1.83M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Bank of New York Mellon's 13F filing for Q1 2026, filed 5 May 2026.